Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on the Safety and Effectiveness of Glofitamab with R-CHOP for High-Risk Patients with Untreated Diffuse Large B-Cell Lymphoma

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a type of cancer called Diffuse Large B-Cell Lymphoma (DLBCL). This is a common form of non-Hodgkin lymphoma, which is a cancer that starts in white blood cells. The study is investigating a treatment that combines a new medication called Glofitamab with a standard chemotherapy regimen known as R-CHOP. R-CHOP includes a combination of drugs: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. The purpose of the study is to evaluate how effective and safe this combination is for patients who have not yet received treatment for their DLBCL and are considered high-risk based on a specific marker in their blood called circulating tumor DNA (ctDNA).

Participants in the study will receive the treatment through an intravenous (IV) infusion, which means the medication is given directly into a vein. The study will monitor the participants over a period to see how well the cancer responds to the treatment and to check for any side effects. The goal is to see if the combination of Glofitamab and R-CHOP can improve the complete response rate, which means the cancer is no longer detectable at the end of the treatment. The study will also look at other outcomes, such as overall survival and progression-free survival, which measures how long patients live without the cancer getting worse.

This trial is important because it explores a new potential treatment option for people with high-risk DLBCL, aiming to improve their chances of recovery and manage the disease more effectively. The study will provide valuable information on the safety and effectiveness of using Glofitamab in combination with R-CHOP, potentially leading to better treatment strategies for this type of lymphoma.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial assessment

    The trial begins with an initial assessment to confirm eligibility. This includes a review of medical history and specific tests to ensure the patient meets the criteria for participation.

    Eligibility criteria include having untreated diffuse large B-cell lymphoma, a life expectancy of at least 6 months, and adequate blood samples for biomarker analysis.

  2. Step 2

    Treatment initiation

    The treatment phase starts with the administration of medications. The patient receives glofitamab and RoActemra (tocilizumab) through an intravenous (IV) infusion.

    The treatment also includes a combination of medications known as R-CHOP, which consists of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.

  3. Step 3

    Treatment cycles

    The treatment is administered in cycles. Each cycle includes the IV infusion of glofitamab and RoActemra, along with the R-CHOP regimen.

    The frequency and duration of each cycle are determined by the study protocol and the patient's response to treatment.

  4. Step 4

    Monitoring and evaluation

    Throughout the trial, the patient's response to treatment is closely monitored. This includes regular medical examinations and imaging tests to assess the effectiveness of the treatment.

    The primary goal is to evaluate the complete response rate at the end of treatment, as determined by specific criteria.

  5. Step 5

    End of treatment assessment

    At the end of the treatment phase, a comprehensive assessment is conducted to determine the overall response to the therapy.

    This includes evaluating the patient's health status and any changes in the condition of the lymphoma.

  6. Step 6

    Follow-up

    After the treatment phase, follow-up visits are scheduled to monitor the patient's long-term health and any potential side effects.

    These visits help ensure the patient's well-being and gather additional data on the treatment's effectiveness.

Who can join the trial?

8 criteria

  • Patients must have **Diffuse Large B-Cell Lymphoma (DLBCL)** that has not been treated before. This includes certain types identified by the World Health Organization.
  • Patients should have an **International Prognostic Index (IPI)** score between 1 and 5. This is a way to assess the risk level of the lymphoma.
  • Patients need to have a **life expectancy** of at least 6 months.
  • Patients must provide adequate blood samples before starting treatment to check for **circulating-tumor DNA (ctDNA)** status. This is a type of DNA found in the blood that can give information about the cancer.
  • Patients should have at least one lymphoma lesion that can be measured using a **PET/CT scan**. This is a type of imaging test that helps to see the cancer.
  • Patients need to have a **left ventricular ejection fraction (LVEF)** of 50% or higher. This is a measure of how well the heart is pumping blood, checked by a heart scan.
  • Both male and female patients can participate.
  • Patients from vulnerable populations are also eligible.

Who cannot join the trial?

9 criteria

  • Patients who have received previous treatment for their Diffuse Large B-Cell Lymphoma (DLBCL) cannot participate. This means if you have already been treated for this type of cancer, you are not eligible.
  • Patients with other types of cancer that are currently being treated or have been treated recently are excluded. This means if you have another cancer that is active or was treated not long ago, you cannot join the study.
  • Patients with serious heart problems are not allowed to participate. This includes conditions like heart failure or recent heart attacks.
  • Patients with severe infections that are not controlled are excluded. This means if you have a serious infection that is not being managed well, you cannot take part.
  • Patients who are pregnant or breastfeeding cannot join the study. This is to ensure the safety of both the mother and the baby.
  • Patients with known allergies to the study drugs or their components are not eligible. If you have a history of allergic reactions to similar medications, you cannot participate.
  • Patients with certain blood disorders that affect normal blood cell production are excluded. This means if you have a condition that impacts how your blood cells are made, you cannot join.
  • Patients who have had a major surgery within a certain time frame before the study starts are not allowed to participate. This is to ensure proper recovery from surgery before joining the study.
  • Patients with a history of drug or alcohol abuse that could interfere with the study are excluded. This means if substance use might affect your ability to follow the study procedures, you cannot take part.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Glofitamab

    is an investigational medication being studied for its potential to treat certain types of cancer. In this trial, it is being tested to see how well it works when combined with other cancer treatments in patients with a specific type of lymphoma.

  • Rituximab

    is a medication used to treat certain types of cancer, including lymphoma. It works by targeting specific cells in the immune system to help the body fight cancer.

  • Cyclophosphamide

    is a chemotherapy drug that helps stop the growth of cancer cells. It is often used in combination with other medications to treat various types of cancer.

  • Doxorubicin

    is a chemotherapy medication used to treat cancer by slowing or stopping the growth of cancer cells. It is commonly used in combination with other cancer treatments.

  • Vincristine

    is a chemotherapy drug that works by inhibiting the growth of cancer cells. It is often used as part of a combination therapy to treat different types of cancer.

  • Prednisone

    is a corticosteroid medication that helps reduce inflammation and suppress the immune system. It is used in cancer treatment to help manage symptoms and improve the effectiveness of other cancer therapies.

What is already known about the treatment

Glofitamab – Glofitamab is administered intravenously and is currently being studied in clinical trials for its effectiveness in treating Diffuse Large B-Cell Lymphoma (DLBCL). It is being evaluated in combination with Rituximab and the chemotherapy regimen CHOP, which includes Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. The main therapeutic indication for Glofitamab is in high-risk patients with untreated DLBCL. At the molecular level, Glofitamab works by engaging T-cells to target and destroy cancer cells. It is classified as a bispecific monoclonal antibody.

Investigated diseases

Diffuse Large B-Cell Lymphoma – This is a type of non-Hodgkin lymphoma that originates in the B-cells, which are a type of white blood cell. It is characterized by rapidly growing tumors in the lymph nodes, spleen, liver, or other organs. The disease can cause symptoms such as swelling of lymph nodes, fever, night sweats, and weight loss. It is considered an aggressive form of lymphoma due to its fast progression. The condition can affect individuals of any age but is more common in older adults. The exact cause of this lymphoma is not well understood, but it involves genetic mutations in the B-cells.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IITrial ID2023-504994-19-00Protocol codeGO43075Estimated enrolment40 patientsSponsorF. Hoffmann-La Roche AG

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.